<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/22F01640-ABE4-47E4-AD36-61CB99D205A4"><gtr:id>22F01640-ABE4-47E4-AD36-61CB99D205A4</gtr:id><gtr:name>Cellectis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CB90AF84-0C45-4AE3-A91A-5F9EDBE89398"><gtr:id>CB90AF84-0C45-4AE3-A91A-5F9EDBE89398</gtr:id><gtr:name>Cell Therapy Catapult</gtr:name><gtr:address><gtr:line1>12th Floor Tower Wing, Guys Hospital, 
Great Maze Pond,</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>SE1 9RT</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:line4>Swindon</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SN2 1ET</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>CO_FUNDER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/22F01640-ABE4-47E4-AD36-61CB99D205A4"><gtr:id>22F01640-ABE4-47E4-AD36-61CB99D205A4</gtr:id><gtr:name>Cellectis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CB90AF84-0C45-4AE3-A91A-5F9EDBE89398"><gtr:id>CB90AF84-0C45-4AE3-A91A-5F9EDBE89398</gtr:id><gtr:name>Cell Therapy Catapult</gtr:name><gtr:address><gtr:line1>12th Floor Tower Wing, Guys Hospital, 
Great Maze Pond,</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>SE1 9RT</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/241F1346-5943-46D8-8C06-9C502D38443C"><gtr:id>241F1346-5943-46D8-8C06-9C502D38443C</gtr:id><gtr:firstName>Farzin</gtr:firstName><gtr:surname>Farzaneh</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FE005896%2F1"><gtr:id>CD2C0D50-5580-4590-9160-381F89D11FFE</gtr:id><gtr:title>BRIC: Packaging cell lines for inherently manufacturable viral vectors</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/E005896/1</gtr:grantReference><gtr:abstractText>Viruses dominate overwhelmingly the types of vectors currently being tested in clinical gene therapy trials and of these retro- and lentiviruses are the most numerous. Until recently two technological problems have hampered progress in gene therapy; production of high titre clinical grade virus and efficient tissue specific targeting. Research at Cambridge and King's College London has addressed the former and led to the development of a novel lentiviral vector packaging cell line in which manufacturability is built into the genome of the packaging cell and co-expressed on the surface of the viruses produced thereafter. We initially used simple retroviral vectors, and latterly the more complex lentiviral vectors based on a core of HIV-1, and have developed strategies for increasing the titre by several orders of magnitude. This is an active area of research amongst which our preliminary work with novel chromatographic techniques and paramagnetic particles set the foundation for a practical and efficient alternative technique to cumbersome ultracentrifugal concentration. For lentiviral vectors we engineered a new producer cell type that provides a biotin tag amenable to various lentiviral vectors produced from these cells using either VSV-G or MLV amphotropic envelopes. We have shown that these bio-lentiviral vectors are produced in the normal manner and only require the presence of biotin in the culture medium to manifest their affinity for streptavidin. Vectors can thus be retained on streptavidin Paramagnetic Magnespheres for infection, or eluted from streptavidin adsorbents. This cell line allows the capture of multiple envelope pseudotypes of lentiviral or MLV derived vectors, enabling production and concentration to titres that are several orders of magnitude higher. Using this scalable protocol we have concentrated lentivirus in excess of 4500-fold in only 3 h and have provided titers for both VSV-G and MLV amphotropic envelope pseudotypes of 1010 IU/ml. However, these viruses could not be easily eluted from adsorbents and required the addition of biotin to the growth medium of the packaging cells. This proposal aims to express the alternative desthiobiotin ligand on the surface of lentiviruses in such a way that elution from adsorbents may be more readily preformed to give higher process yields and the addition of an affinity ligand binding precursor to growth medium is avoided.</gtr:abstractText><gtr:technicalSummary>It addresses Improved Downstream Processing for nanoscale vectors, transferring in-built manufacturability from laboratory to GMP practice. It provides virus manufacturers with tools to engineer viral envelopes in a way that uncertainties in downstream processing are avoided whilst overcoming problems of low titre that have hampered the field. These tools will bring increased predictability for bioprocessing, including improved scale-up and reproducibility and so enable increased speed to clinic and market.</gtr:technicalSummary><gtr:fund><gtr:end>2010-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2007-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>251318</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cell Therapy Catapult</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Vector Industrialisation Project</gtr:description><gtr:id>86660F61-1561-44BC-9371-D5FD69EBBFB7</gtr:id><gtr:impact>This project is contributing to the development of new therapies and therapeutic strategies, particularly with respect of the industrial scale manufacture of cell and gene therapy vectors, thus contributing both to better health care and to creation of wealth, including inward investment from outside the UK.</gtr:impact><gtr:outcomeId>56e545de11e208.59311162-1</gtr:outcomeId><gtr:partnerContribution>Funding of the initial studies, providing the vector manufacturing cell line and expertise in project management, accurate calculation of costs of goods. Cell and Gene Therapy Catapult is also providing expertise in the development of strategies aimed at reducing the cost of goods, risk-reduction for manufacturing campaigns and strategies for efficient large scale manufacture of clinical grade vectors. This project is underpinned by two previous BBSRC grants and directly affected by our current BBSRC supported project.</gtr:partnerContribution><gtr:piContribution>The aim of this recently initiated project is the development of GMP compatible procedures for the industrialisation of gene therapy products. The main focus of this specific project is the development of cell line/s with characteristics needed for large scale manufacture of a retrovirus vector encoding a specific T cell receptor (TCR).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cellectis</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Cellectis: Production of viral vectors (primarily lentivirus), and gene modified cells, for clinical applications of cell and gene therapy</gtr:description><gtr:id>20EAC471-9999-4371-9DE1-054F19AF9898</gtr:id><gtr:impact>The development of allogeneic CAR-T cells (referred to as UniCAR-T) for the treatment of malignant disease. There has also been substantial inward investment (over &amp;pound;11,000,000 between 2016 and 2019 from Cellectis alone) underpining further developments that we expect to culminate in substantially larger collaborations with other pharmaceuticaal companies (active discussions in progress with Cell Therapy Catapult, Pfizer and Servier). This collaboration has also resulted in a separate collaboration with a UK based start-up company - Autolus (reported as a separate collaboration).</gtr:impact><gtr:outcomeId>56e54c27b0c147.17704898-1</gtr:outcomeId><gtr:partnerContribution>Provision of funding and know-how in specific areas (e.g. site directed endonuclease mediated inhibition of endogenous T cell receptors, in order to allow the generation of allogeneic (off-the-shelf) Chimeric Antigen Receptor (CAR) T cells for the treatment of malignant disease. This project is directly supported by BB/N003853/1 and assisted by the outputs from our previous BBSRC grants: BB/E005896/1, BB/D014301/1 and BB/K013785/1.</gtr:partnerContribution><gtr:piContribution>Development and production of multiple lentivirus and retrovirus vectors for a range of clinical studies in collaboration with both academic and industry partners, the largest of which is the collaboration with Cellectis culminating in over &amp;pound;1.6 million of funding todate, plus a new contract for &amp;pound;10.1 million over the next 3 years.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1200000</gtr:amountPounds><gtr:country>Singapore, Republic of</gtr:country><gtr:currCode>SGD</gtr:currCode><gtr:currCountryCode>Singapore</gtr:currCountryCode><gtr:currLang>en_SG</gtr:currLang><gtr:description>An immunisation strategy to prevent hepatocellular carcinoma</gtr:description><gtr:end>2015-07-02</gtr:end><gtr:fundingOrg>National Medical Research Council NMRC</gtr:fundingOrg><gtr:id>F8429086-CF72-4952-8104-38422B220489</gtr:id><gtr:outcomeId>56e550328537b7.19557861</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Core Suppport for GMP facility</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Experimental Cancer Medicine Centre Network (ECMC)</gtr:fundingOrg><gtr:id>4DD4A65F-40B5-4B06-A40D-42CAD58DCA37</gtr:id><gtr:outcomeId>56e54f5d8ff5f9.77055682</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1093000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pre-emptive immune therapy to prevent relapse of myeloid malignancies</gtr:description><gtr:end>2017-02-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:fundingRef>LLR 13007</gtr:fundingRef><gtr:id>B5883035-50C4-4F3D-B1EB-E7B0C0D5695F</gtr:id><gtr:outcomeId>56e54da10f7f94.59517190</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>900000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR i4i Invention for Innovation (i4i) Programme</gtr:department><gtr:description>Next generation CAR19 studies - Collaboration with Martin Pule et al at UCL</gtr:description><gtr:end>2019-04-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>II-C3-0714-20005</gtr:fundingRef><gtr:id>F11907FC-B6E8-49F6-9D51-A37569A9271C</gtr:id><gtr:outcomeId>56e5536b884628.81543033</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>540000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Translational Research Program: Activation of multiple adjuvant pathways to improve AML vaccine efficacy</gtr:description><gtr:end>2016-06-02</gtr:end><gtr:fundingOrg>The Leukemia &amp; Lymphoma Society</gtr:fundingOrg><gtr:id>59DF0E08-3017-42B7-970A-AE69144BBE8B</gtr:id><gtr:outcomeId>56e5525f6d72c8.12574467</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>This project, in combination with BB/D014301/1, has allowed us to develop novel procedure for attachment of biomarkers to viral vectors, and to establish GLP and GMP compliant procedures for the conduct of immunological assays on patient samples and for the manufacture of vectors that are used in clinical trials. The IP, techniques and facilities developed have directly contributed to the attraction of substantial grant funding and3 major industrial collaborations:
1) Roche Pharmaceuticals for the development and assessment of clinical potential of glycoengineered antibodies - value of contract research to KCL &amp;pound;2,400,000 between 2009 and 2013.
2) Northwest Biotech (USA) for the production of dendritic cell vaccine (DCVax) used in a sponsored Phase-III clinical trial - Value &amp;pound;2,600,000 between 2012 and 2016.
3) Cellectis (France) for the development of lentivirus vectors for the manufacture of Chimeric Antigen Receptor T cells (CAR-T cells) - Value &amp;pound;10,100,000 between 2014 and 2019.</gtr:description><gtr:firstYearOfImpact>2009</gtr:firstYearOfImpact><gtr:id>953836F3-C71A-4FF9-8164-3CA38230C534</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>56e48652763a28.51994468</gtr:outcomeId><gtr:sector>Education,Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The production of viral vectors, in particular lentivirus and gamma-retrovirus in sufficient quantities and able to meet the regulatory standards of quality is particularly challenging. Using the technologies that were developed as part of our BBSRC supported projects, we have established a range of manufacturing, purification and concentration strategies that have enabled us to manufacture the largest number (academia or industry) of retroviral and lentivirus vectors for regulatory approved clinical trials in Europe. This extensive research and development programme has now culminated in over &amp;pound;15 million pound of income (2012 to 2019) for King's College London from overseas based companies.</gtr:description><gtr:grantRef>BB/E005896/1</gtr:grantRef><gtr:id>C0A32024-4C37-49E5-825C-D3EC09B6C47C</gtr:id><gtr:impact>The background manufacturing IP and know-how is licensed (non-exclusive) to Cellectis and to Cell Therapy Catapult. Discussions are in progress with other organisations in taking similar non-exclusive licenses.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>56e55b46847bb8.13427703</gtr:outcomeId><gtr:protection>Protection not required</gtr:protection><gtr:title>Development of GMP compliant manufacturing strategies for the production of clinical grade viral vectors</gtr:title><gtr:yearProtectionGranted>2016</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>We have developed procedures for the fast manufacture of retrovirus and lentivirus vectors in compliance with the regulatory requirements for clinical use (GMP compliant procedures). These highly optimised procedures have enabled the production of high titre vectors (about 50,000 million infectious units of vector) from relatively small scale cultures (circa 10 litres), with greater than 50% recovery (frequently in excess of 70%) and minimal quantities of contaminating proteins and nucleic acids. This knowhow has recently been licensed on non-exclusive deals to the industry (Cellectis) in contracts producing in excess of &amp;pound;15 million pounds of income over the next 3 years.</gtr:description><gtr:grantRef>BB/E005896/1</gtr:grantRef><gtr:id>7112B439-0E47-4529-91C9-43C7AA8F428D</gtr:id><gtr:impact>We have produced, for regulatory approved clinical trials, the largest number of lenti- and retroviral vectors in Europe. Each of the 4 BBSRC supported projects have contributed to this outcome. We are now extending this expertise with a view to similarly innovative manufacture of Adeno Associated Virus (AAV) manufacture for clinical use.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>58dd4a03bc3529.52671325</gtr:outcomeId><gtr:protection>Protection not required</gtr:protection><gtr:title>The processes developed in the course of this study have directly contributed to the success of subsequent contracts with the Industry, including Autolus and Cellectis (biotech and pharmaceutical companies.</gtr:title><gtr:yearProtectionGranted>2016</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>Development of a cell line (BL15) in which introduction of a series of bacterial genes has enabled the conversion of a precursor of biotin (DAPA), provided by addition to the culture media, into biotin which is then displayed on the surface of the cell, thus allowing the biotinylation of lentivirus vector produced from these cells. These cells are now used for the generation of virus that can be readily captured, purified and concentrated on streptavidin paramagnetic beads. This development has results in attraction of several million of industrial contracts from the pharmaceutical industry and a large number of subsequent grants form research councils, NIHR and the Leukaemia Lymphoma Research (now Blood Wise)</gtr:description><gtr:exploitationPathways>Novel manufacturing activities for the production of viral vectors for cell and gene therapy applications are now being developed in collaboration with other academic centres, supported by research grants, and in collaboration with Industry (Cell Therapy Catapult, Cellectis, Autolus and Pfizer).</gtr:exploitationPathways><gtr:id>D3F54883-457E-4E38-80CF-565F413B5EAB</gtr:id><gtr:outcomeId>56e198bc7d1fc9.29967923</gtr:outcomeId><gtr:sectors><gtr:sector>Education,Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>5ACC9314-87BD-4B1C-98BA-2A665995CD39</gtr:id><gtr:title>Transient Expression of Green Fluorescent Protein in Integrase-Defective Lentiviral Vector-Transduced 293T Cell Line.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/09948ad04d13498a0c35d47964163e2f"><gtr:id>09948ad04d13498a0c35d47964163e2f</gtr:id><gtr:otherNames>Nordin F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>590058c45ce8f6.20336423</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA677B7D-52C7-4622-B2F6-3D2FB18BCDAE</gtr:id><gtr:title>Clinical Grade Lentiviral Vector Production for the Inherited Skin Disease, Netherton Syndrome</gtr:title><gtr:parentPublicationTitle>MOLECULAR THERAPY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/22c65c6ed8ee74bcaaec051db76bc0e5"><gtr:id>22c65c6ed8ee74bcaaec051db76bc0e5</gtr:id><gtr:otherNames>Ghani Sumera</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>56e1ab8dc14729.03818903</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A4A8F8C-81D9-4D0C-BCF6-80F3F6EDB0DB</gtr:id><gtr:title>CD80/IL-2 mediated inhibition of multiple myeloma induced suppression of NK cell activity</gtr:title><gtr:parentPublicationTitle>HUMAN GENE THERAPY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f439f39a89d6cae4f08e3176f63eb02"><gtr:id>7f439f39a89d6cae4f08e3176f63eb02</gtr:id><gtr:otherNames>Giunti Giulia</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn><gtr:outcomeId>56e1ab8e122e76.60679445</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C26B32F-78FB-49C2-9350-4C2677A6C559</gtr:id><gtr:title>Adeno-associated virus-mediated expression of kallistatin suppresses local and remote hepatocellular carcinomas.</gtr:title><gtr:parentPublicationTitle>The journal of gene medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/39ecc5f1beb61b1b96b971ac921ada79"><gtr:id>39ecc5f1beb61b1b96b971ac921ada79</gtr:id><gtr:otherNames>Tse LY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1099-498X</gtr:issn><gtr:outcomeId>56e03c1ee891f2.98377131</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E2D59E0-0D71-474F-808F-79958E913403</gtr:id><gtr:title>NK Cell-Mediated Immunologic Responses Against Myeloma by B7-1 (CD80)/IL-2 Immune Gene Therapy</gtr:title><gtr:parentPublicationTitle>CLINICAL LYMPHOMA &amp; MYELOMA</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb01332cf666b9f770f292b40619b070"><gtr:id>eb01332cf666b9f770f292b40619b070</gtr:id><gtr:otherNames>Guven H.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1557-9190</gtr:issn><gtr:outcomeId>56e1ab90624a14.79669912</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E4B0CDF-66ED-4677-8546-ED17D5EAB7BC</gtr:id><gtr:title>Long-term efficacy and pharmacodynamic parameter analysis in pretreated KRAS-mutant metastatic colorectal carcinoma (mCRC) patients treated with RG7160 (GA201), an antibody-dependent cellular cytotoxicity (ADCC)-enhanced monoclonal anti-EGFR antibody</gtr:title><gtr:parentPublicationTitle>JOURNAL OF CLINICAL ONCOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b3fdff8dbd71a640c0eac0f77f251c29"><gtr:id>b3fdff8dbd71a640c0eac0f77f251c29</gtr:id><gtr:otherNames>Delord Jean-Pierre</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>56e1ab8cd7ad87.85522486</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1C1D54E-FE13-40E2-B447-A339EA970766</gtr:id><gtr:title>Production and first-in-man use of T cells engineered to express a HSVTK-CD34 sort-suicide gene.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91649be5270d54cdaa9c14dd4b89f0ac"><gtr:id>91649be5270d54cdaa9c14dd4b89f0ac</gtr:id><gtr:otherNames>Zhan H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56e03c0ebfca63.05910384</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>931B1A8F-6951-4E73-A1B9-A83807A91DB5</gtr:id><gtr:title>Efficacy, Safety evaluation and GMP development of lentiviral vector-induced multivalent dendritic cells for melanoma immunotherapy</gtr:title><gtr:parentPublicationTitle>HUMAN GENE THERAPY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1413aab73219922d35992e4e77374422"><gtr:id>1413aab73219922d35992e4e77374422</gtr:id><gtr:otherNames>Stripecke R.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn><gtr:outcomeId>56e1ab8ec5a276.47511677</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB7543B8-1CAF-40B6-B68D-5D0F99D55B01</gtr:id><gtr:title>Preparation and characterization of prostate cell lines for functional cloning studies to identify regulators of apoptosis.</gtr:title><gtr:parentPublicationTitle>Journal of andrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59460f82b4f3c554f1f2872bf40d05e5"><gtr:id>59460f82b4f3c554f1f2872bf40d05e5</gtr:id><gtr:otherNames>Pickard MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0196-3635</gtr:issn><gtr:outcomeId>56e03c12c25441.21539401</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF4103B3-61E9-488C-8805-236C584FEAA7</gtr:id><gtr:title>Simple magnetic cell patterning using streptavidin paramagnetic particles.</gtr:title><gtr:parentPublicationTitle>Experimental biology and medicine (Maywood, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/906500d20e1a2e875bc6fe2abeced17d"><gtr:id>906500d20e1a2e875bc6fe2abeced17d</gtr:id><gtr:otherNames>Ho VH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1535-3699</gtr:issn><gtr:outcomeId>56e03c1376d9e0.34464564</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85F0E3D7-4432-4563-9922-21061E55BCF2</gtr:id><gtr:title>WFDC1/ps20 is a novel innate immunomodulatory signature protein of human immunodeficiency virus (HIV)-permissive CD4+ CD45RO+ memory T cells that promotes infection by upregulating CD54 integrin expression and is elevated in HIV type 1 infection.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b5cc624bad12d0c96969bf1c791498c"><gtr:id>8b5cc624bad12d0c96969bf1c791498c</gtr:id><gtr:otherNames>Alvarez R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>56e03c1f45d1d4.14264156</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B7DAF8C-B618-4A78-B31C-ABF5AFDEA9BD</gtr:id><gtr:title>The use of PARP inhibitors in cancer therapy: use as adjuvant with chemotherapy or radiotherapy; use as a single agent in susceptible patients; techniques used to identify susceptible patients.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5992f83b27a14be0277f5504dc5d2b75"><gtr:id>5992f83b27a14be0277f5504dc5d2b75</gtr:id><gtr:otherNames>Shall S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>56e03c10328557.16277034</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B82F106-2F45-4563-B3BE-5B1800A911F3</gtr:id><gtr:title>Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd2ca761a141ca7db238491b9127a7d8"><gtr:id>bd2ca761a141ca7db238491b9127a7d8</gtr:id><gtr:otherNames>Qasim W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>5900592e9862a5.18246622</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C87F1274-E70B-4803-BE67-127D58DF1719</gtr:id><gtr:title>Phase I study protocol for ex vivo lentiviral gene therapy for the inherited skin disease, Netherton syndrome.</gtr:title><gtr:parentPublicationTitle>Human gene therapy. Clinical development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/743a9330295bcb83f675789e068a5c3e"><gtr:id>743a9330295bcb83f675789e068a5c3e</gtr:id><gtr:otherNames>Di WL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2324-8637</gtr:issn><gtr:outcomeId>56e03c0e1c1640.35982019</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>278B2E35-3901-4D47-8490-464932EC327A</gtr:id><gtr:title>Inhibition of poly ADP ribose polymerase (PARP) induces cell death in leukaemic cell lines alone or synergistically with histone deacetylase inhibitors: potential for anti-leukaemia therapy</gtr:title><gtr:parentPublicationTitle>LEUKEMIA RESEARCH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07d80969ece1f79260f7776a905cc0a0"><gtr:id>07d80969ece1f79260f7776a905cc0a0</gtr:id><gtr:otherNames>Gaymes T. J.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0145-2126</gtr:issn><gtr:outcomeId>56e1ab91882416.26414529</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B87FE55-04E9-46E8-957B-A02275E17448</gtr:id><gtr:title>Lytic activity against primary AML cells is stimulated in vitro by an autologous whole cell vaccine expressing IL-2 and CD80.</gtr:title><gtr:parentPublicationTitle>Cancer immunology, immunotherapy : CII</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f26c68aa9ecea466134c7126ebe179aa"><gtr:id>f26c68aa9ecea466134c7126ebe179aa</gtr:id><gtr:otherNames>Hardwick N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0340-7004</gtr:issn><gtr:outcomeId>56e03c11404be7.40182735</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F002A781-D3BA-465E-8113-574B8FB8CCDC</gtr:id><gtr:title>Preparation for a Phase I/II Clinical Trial of T Cell Suicide Gene Therapy Following Haematopoietic Stem Cell Transplantation in Children</gtr:title><gtr:parentPublicationTitle>HUMAN GENE THERAPY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e015d63c6af0d4019cb8444f759b8df3"><gtr:id>e015d63c6af0d4019cb8444f759b8df3</gtr:id><gtr:otherNames>Zhan H.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn><gtr:outcomeId>56e1ab8f370989.45416893</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3DE635B4-5927-4E97-9642-716B427D7073</gtr:id><gtr:title>GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c69e0118dcdf559e4f85b0f777ea6e3"><gtr:id>6c69e0118dcdf559e4f85b0f777ea6e3</gtr:id><gtr:otherNames>Mourtada-Maarabouni M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>56e03c13c24444.20703819</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3DA2DAE1-133F-4E96-85AF-A5A7BE7FB331</gtr:id><gtr:title>Phase 1 Study of HSVTK-CD34 Modified T Cells Therapy Following Haematopoietic Stem Cell Transplantation (HSCT) without Serotherapy</gtr:title><gtr:parentPublicationTitle>MOLECULAR THERAPY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/53dc0e021209069ebd605677d5341f31"><gtr:id>53dc0e021209069ebd605677d5341f31</gtr:id><gtr:otherNames>Zhan Hong</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>56e1ab8d7aa628.10457481</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDF1A533-0CA2-4759-8565-ACE496173426</gtr:id><gtr:title>Apoptosis Suppression by Candidate Oncogene PLAC8 is Reversed in Other Cell Types</gtr:title><gtr:parentPublicationTitle>CURRENT CANCER DRUG TARGETS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/29a3bb21092a8d968032f51c761624e0"><gtr:id>29a3bb21092a8d968032f51c761624e0</gtr:id><gtr:otherNames>Mourtada-Maarabouni Mirna</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1568-0096</gtr:issn><gtr:outcomeId>56e1ab8d569111.50239692</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D85AD036-9395-483F-BC07-8B26131956D7</gtr:id><gtr:title>Identity, potency, in vivo viability, and scaling up production of lentiviral vector-induced dendritic cells for melanoma immunotherapy.</gtr:title><gtr:parentPublicationTitle>Human gene therapy methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e502bdff32788aaa0b74f26351d3421c"><gtr:id>e502bdff32788aaa0b74f26351d3421c</gtr:id><gtr:otherNames>Pincha M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1946-6536</gtr:issn><gtr:outcomeId>56e1ab901fb884.57713691</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>27B51741-0F63-4534-BE08-5650CD958B87</gtr:id><gtr:title>Active dendritic cell immunotherapy for glioblastoma: Current status and challenges.</gtr:title><gtr:parentPublicationTitle>British journal of neurosurgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d34d3ede29e8ba6b5936802fcccc0bfc"><gtr:id>d34d3ede29e8ba6b5936802fcccc0bfc</gtr:id><gtr:otherNames>Polyzoidis S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0268-8697</gtr:issn><gtr:outcomeId>56e03c0d39a227.94119318</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>29D59048-0487-40A5-9823-E68C70581704</gtr:id><gtr:title>First-in-man use of T cells engineered to express a HSVTK-CD34 sort-suicide gene</gtr:title><gtr:parentPublicationTitle>HUMAN GENE THERAPY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/53dc0e021209069ebd605677d5341f31"><gtr:id>53dc0e021209069ebd605677d5341f31</gtr:id><gtr:otherNames>Zhan Hong</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn><gtr:outcomeId>56e1ab8d25a037.64399164</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC9E3843-DF7F-4DDB-9841-EF61E29E5DEB</gtr:id><gtr:title>Metabolic Biotinylation of Lentiviral Vectors</gtr:title><gtr:parentPublicationTitle>HUMAN GENE THERAPY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5dbffe988f6a65dbedc00c26af687e0"><gtr:id>b5dbffe988f6a65dbedc00c26af687e0</gtr:id><gtr:otherNames>Mondragon Angeles</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn><gtr:outcomeId>56e1ab8f77fb50.55984321</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10A8A5D0-6EB5-49B8-9B78-825F2F0BBA9B</gtr:id><gtr:title>A critical role for non-coding RNA GAS5 in growth arrest and rapamycin inhibition in human T-lymphocytes.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1acf39a83094a65d3848318c2954b2ae"><gtr:id>1acf39a83094a65d3848318c2954b2ae</gtr:id><gtr:otherNames>Williams GT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>56e03c0ff2b429.03696811</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7295EA5C-A785-4B7E-A02F-66814B8E51C2</gtr:id><gtr:title>Monocytes transduced with tricistronic lentiviral vectors in a closed bag system induce differentiation of loaded &amp;quot;SMART-DCs&amp;quot; for melanoma immunotherapy</gtr:title><gtr:parentPublicationTitle>HUMAN GENE THERAPY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1413aab73219922d35992e4e77374422"><gtr:id>1413aab73219922d35992e4e77374422</gtr:id><gtr:otherNames>Stripecke R.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn><gtr:outcomeId>56e1ab8f59a0e0.55581198</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8FD45EF2-1D3A-472F-84DF-4BEC268B0B17</gtr:id><gtr:title>Immobilized metal affinity chromatography of histidine-tagged lentiviral vectors using monolithic adsorbents.</gtr:title><gtr:parentPublicationTitle>Journal of chromatography. A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/29091dfa0a7624fca6dba4fe584c0f22"><gtr:id>29091dfa0a7624fca6dba4fe584c0f22</gtr:id><gtr:otherNames>Cheeks MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9673</gtr:issn><gtr:outcomeId>56e03c1e6eb563.30419399</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>982C58E5-C8E4-4CDA-8313-377D8D81756A</gtr:id><gtr:title>Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma.</gtr:title><gtr:parentPublicationTitle>European journal of cancer (Oxford, England : 1990)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5fd746754a5bc6bd9c5f37260f87931"><gtr:id>b5fd746754a5bc6bd9c5f37260f87931</gtr:id><gtr:otherNames>Delord JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0959-8049</gtr:issn><gtr:outcomeId>56e03c0dd202c9.13748369</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>462676FB-BF2D-4380-859A-9FCF0A1B0101</gtr:id><gtr:title>Transactivator protein: An alternative for delivery of recombinant proteins for safer reprogramming of induced Pluripotent Stem Cell.</gtr:title><gtr:parentPublicationTitle>Virus research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/09948ad04d13498a0c35d47964163e2f"><gtr:id>09948ad04d13498a0c35d47964163e2f</gtr:id><gtr:otherNames>Nordin F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0168-1702</gtr:issn><gtr:outcomeId>590057f0c50cd6.49094396</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D3B3A93-CF7E-46EF-8D7A-F35978B628F4</gtr:id><gtr:title>CD80-IL2 expressing myeloma cells for immune gene therapy of multiple myeloma</gtr:title><gtr:parentPublicationTitle>BRITISH JOURNAL OF HAEMATOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ca3444c94f75612214be46b591504f17"><gtr:id>ca3444c94f75612214be46b591504f17</gtr:id><gtr:otherNames>Giunti G.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>56e1ab8e35d108.45310015</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D635A476-23E1-4756-801C-281BB7BD9212</gtr:id><gtr:title>A Functional Assay for MicroRNA Target Identification and Validation</gtr:title><gtr:parentPublicationTitle>BLOOD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a54e02d793475d5eb845504e2d417e79"><gtr:id>a54e02d793475d5eb845504e2d417e79</gtr:id><gtr:otherNames>Gaken Joop</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>56e1ab8ff3c275.54225944</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91882A13-E5D1-4A4E-825A-BDD4CEF49479</gtr:id><gtr:title>Inhibition of angiogenesis and HCT-116 xenograft tumor growth in mice by kallistatin</gtr:title><gtr:parentPublicationTitle>WORLD JOURNAL OF GASTROENTEROLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e47455a23aa569e4ea72b226a4804c08"><gtr:id>e47455a23aa569e4ea72b226a4804c08</gtr:id><gtr:otherNames>Diao Yong</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1007-9327</gtr:issn><gtr:outcomeId>56e1ab91a7d037.53180839</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7FE8CA3A-6D36-4632-A214-841AB377A0A6</gtr:id><gtr:title>Optimised concentration and purification of retroviruses using membrane chromatography.</gtr:title><gtr:parentPublicationTitle>Journal of chromatography. A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/636bdb1930ee7959b3a9bb484090496b"><gtr:id>636bdb1930ee7959b3a9bb484090496b</gtr:id><gtr:otherNames>McNally DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9673</gtr:issn><gtr:outcomeId>56e03c0d864df2.79415689</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A104BF8-9D3E-4514-B526-D2DF42CA3328</gtr:id><gtr:title>A lentiviral vector manufactured under GMP for a Phase I study in Acute Myeloid Leukaemia - manufacture summary, safety testing, application and post-administration safety-monitoring</gtr:title><gtr:parentPublicationTitle>HUMAN GENE THERAPY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89d71a156a5a221684ca020eda19cd7b"><gtr:id>89d71a156a5a221684ca020eda19cd7b</gtr:id><gtr:otherNames>Chan Lucas</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn><gtr:outcomeId>56e1ab8e5784a9.05074796</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1071A194-E043-47CB-8BCD-2F9232AC9EC2</gtr:id><gtr:title>Are snoRNAs and snoRNA host genes new players in cancer?</gtr:title><gtr:parentPublicationTitle>Nature reviews. Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1acf39a83094a65d3848318c2954b2ae"><gtr:id>1acf39a83094a65d3848318c2954b2ae</gtr:id><gtr:otherNames>Williams GT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1474-175X</gtr:issn><gtr:outcomeId>56e03c0fc64ac4.75987944</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D78FFA00-4E06-4CB5-91BC-0DC78A5F9FA0</gtr:id><gtr:title>Peptide vaccination using combined adjuvants for synergistic activation of cellular immunity (CASAC) promotes potent WT1-specific immune responses in an in vivo mouse model</gtr:title><gtr:parentPublicationTitle>BRITISH JOURNAL OF HAEMATOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ad526060a008ded9980058045c41f5a"><gtr:id>9ad526060a008ded9980058045c41f5a</gtr:id><gtr:otherNames>Krishnamurthy P.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>56e1ab8cb4c307.59625158</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C452A216-700A-4F48-BE43-CB0981922300</gtr:id><gtr:title>Crucial roles for protein kinase C isoforms in tumor-specific killing by apoptin.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b173b42278a891646058b59fa4cf379c"><gtr:id>b173b42278a891646058b59fa4cf379c</gtr:id><gtr:otherNames>Jiang J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>56e03c10869684.49270778</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83DF09BB-1A65-4525-8B46-5291D875CDFC</gtr:id><gtr:title>Delivery of therapeutic proteins as secretable TAT fusion products.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1432aa770c370f47532546a3daa99c38"><gtr:id>1432aa770c370f47532546a3daa99c38</gtr:id><gtr:otherNames>Flinterman M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>56e03c1e428203.24193201</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A669F24C-03E3-4EC1-8D6A-6F212369F311</gtr:id><gtr:title>Lentivirus capture directly from cell culture with Q-functionalised microcapillary film chromatography.</gtr:title><gtr:parentPublicationTitle>Journal of chromatography. A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a6ad3fd452727615f29546b2658c7ff6"><gtr:id>a6ad3fd452727615f29546b2658c7ff6</gtr:id><gtr:otherNames>Darton NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9673</gtr:issn><gtr:outcomeId>56e03c0eebccb3.09832649</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3838F654-593B-48FA-BE07-9303B07EA842</gtr:id><gtr:title>Lentiviral Engineered Fibroblasts Expressing Codon-Optimized COL7A1 Restore Anchoring Fibrils in RDEB.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3c6297244b2522e5bcfc25bb0ee42c14"><gtr:id>3c6297244b2522e5bcfc25bb0ee42c14</gtr:id><gtr:otherNames>Georgiadis C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>56e03c0ccb44f2.02404360</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98B05377-F531-4EA7-8B83-52F4842CA20C</gtr:id><gtr:title>Inhibition of angiogenesis and HCT-116 xenograft tumor growth in mice by kallistatin.</gtr:title><gtr:parentPublicationTitle>World journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/547dc77207d592772383be2f80749e98"><gtr:id>547dc77207d592772383be2f80749e98</gtr:id><gtr:otherNames>Diao Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1007-9327</gtr:issn><gtr:outcomeId>56e03c14337859.74110474</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B0A0BCD-7285-4C63-B38D-A31AA6C305C3</gtr:id><gtr:title>A functional assay for microRNA target identification and validation.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7176dbc4e28630e2de3e92aa50523ac8"><gtr:id>7176dbc4e28630e2de3e92aa50523ac8</gtr:id><gtr:otherNames>G?ken J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>56e03c0f1bbdd0.10387246</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DDE3529A-DA42-493B-8405-D71CE829DC99</gtr:id><gtr:title>Lentivirus-induced 'Smart' dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma.</gtr:title><gtr:parentPublicationTitle>Gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c199b3efd654a479f7931a1b2a91ed72"><gtr:id>c199b3efd654a479f7931a1b2a91ed72</gtr:id><gtr:otherNames>Sundarasetty BS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0969-7128</gtr:issn><gtr:outcomeId>56e03c0cf38ad6.14135981</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0BB062BA-5D37-41C8-AF04-FF48B7469B99</gtr:id><gtr:title>Pathway to delivery of a gene modified T cell Investigational Medicinal Product (IMP)</gtr:title><gtr:parentPublicationTitle>HUMAN GENE THERAPY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e015d63c6af0d4019cb8444f759b8df3"><gtr:id>e015d63c6af0d4019cb8444f759b8df3</gtr:id><gtr:otherNames>Zhan H.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn><gtr:outcomeId>56e1ab8e74da51.22543525</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F574E1C-A418-42F1-9EA7-3D0C00A55431</gtr:id><gtr:title>Lentiviral vector-induced SmartDC-TRP2 for melanoma immunotherapy: immunemonitoring validation assays and GMP development</gtr:title><gtr:parentPublicationTitle>HUMAN GENE THERAPY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1413aab73219922d35992e4e77374422"><gtr:id>1413aab73219922d35992e4e77374422</gtr:id><gtr:otherNames>Stripecke R.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn><gtr:outcomeId>56e1ab8d9dd113.16474085</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13DB318F-15D9-4479-A87E-F2AE210E8D53</gtr:id><gtr:title>Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9cc0636c58e0bf73720380929b56da1"><gtr:id>a9cc0636c58e0bf73720380929b56da1</gtr:id><gtr:otherNames>Oppenheim DE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>56e03c0dab2672.91203958</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC8550E6-6EC7-44D5-A65D-B971AE29E502</gtr:id><gtr:title>Affinity recovery of lentivirus by diaminopelargonic acid mediated desthiobiotin labelling.</gtr:title><gtr:parentPublicationTitle>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/236f4fb0ad950ba127647144b62c1fce"><gtr:id>236f4fb0ad950ba127647144b62c1fce</gtr:id><gtr:otherNames>Chen R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1570-0232</gtr:issn><gtr:outcomeId>56e03c10b1b469.86358578</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3594D0E0-8DA9-4DDB-AAFE-2DA9727A3A66</gtr:id><gtr:title>Development of SMART-DC co-expressing truncated WT1 for stimulation and expansion of T cells against leukemia relapse</gtr:title><gtr:parentPublicationTitle>HUMAN GENE THERAPY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcb5e2e43eb8cc81d865356f4da0e631"><gtr:id>dcb5e2e43eb8cc81d865356f4da0e631</gtr:id><gtr:otherNames>Sundarasetty Bala Sai</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn><gtr:outcomeId>56e1ab90d0c6d6.11078309</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E02C6097-73E5-45F7-8070-2315E3992F88</gtr:id><gtr:title>Human Gyrovirus Apoptin shows a similar subcellular distribution pattern and apoptosis induction as the chicken anaemia virus derived VP3/Apoptin.</gtr:title><gtr:parentPublicationTitle>Cell death &amp; disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/765f069a96207a8a885efe34762e0d53"><gtr:id>765f069a96207a8a885efe34762e0d53</gtr:id><gtr:otherNames>Bullenkamp J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>56e03c0f4bbc06.39092759</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FAE02816-FE2B-4FFC-A8B1-E6E7F1753F49</gtr:id><gtr:title>Human CD80/IL2 lentivirus transduced acute myeloid leukaemia cells enhance cytolytic activity in vitro in spite of an increase in regulatory CD4+ T cells in a subset of cultures.</gtr:title><gtr:parentPublicationTitle>Cancer immunology, immunotherapy : CII</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6cfb5657d12e7354b8b9af96063c75a2"><gtr:id>6cfb5657d12e7354b8b9af96063c75a2</gtr:id><gtr:otherNames>Ingram W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0340-7004</gtr:issn><gtr:outcomeId>56e03c120c9b27.31223642</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0E240A2A-2D9A-40AC-A293-20D5501E6898</gtr:id><gtr:title>The combined molecular adjuvant CASAC enhances the CD8+ T cell response to a tumor-associated self-antigen in aged, immunosenescent mice.</gtr:title><gtr:parentPublicationTitle>Immunity &amp; ageing : I &amp; A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bdee00795070cd198e0921a034159095"><gtr:id>bdee00795070cd198e0921a034159095</gtr:id><gtr:otherNames>Tye GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1742-4933</gtr:issn><gtr:outcomeId>56e03c0d5fca69.14215963</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2820F85F-61E7-4575-A887-02B36EE1008A</gtr:id><gtr:title>Development of therapeutic vaccines for cancer and chronic infections: from AML to HBV</gtr:title><gtr:parentPublicationTitle>HUMAN GENE THERAPY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54a97e2e8f661d799338885b7d91133b"><gtr:id>54a97e2e8f661d799338885b7d91133b</gtr:id><gtr:otherNames>Farzaneh F.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn><gtr:outcomeId>56e1ab8ee36a25.10901398</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>76B8ABDA-D143-4D57-9B97-A1972BB83835</gtr:id><gtr:title>Characterization of SPINK5-transduced keratinocytes under good manufacturing practice conditions for Netherton syndrome</gtr:title><gtr:parentPublicationTitle>BRITISH JOURNAL OF DERMATOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ba555a22e36601c7d7127622329bfe7"><gtr:id>7ba555a22e36601c7d7127622329bfe7</gtr:id><gtr:otherNames>Petrova A.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>56e1ab8c5b3a49.29351784</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3697E94-9B79-4B47-A368-218647A490AA</gtr:id><gtr:title>Growth arrest in human T-cells is controlled by the non-coding RNA growth-arrest-specific transcript 5 (GAS5)</gtr:title><gtr:parentPublicationTitle>Journal of Cell Science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c69e0118dcdf559e4f85b0f777ea6e3"><gtr:id>6c69e0118dcdf559e4f85b0f777ea6e3</gtr:id><gtr:otherNames>Mourtada-Maarabouni M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>56e1ab8fb61ee3.13387447</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A2C9C92-0841-4F27-8D79-C30C1F06E15F</gtr:id><gtr:title>Growth arrest in human T-cells is controlled by the non-coding RNA growth-arrest-specific transcript 5 (GAS5).</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c69e0118dcdf559e4f85b0f777ea6e3"><gtr:id>6c69e0118dcdf559e4f85b0f777ea6e3</gtr:id><gtr:otherNames>Mourtada-Maarabouni M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>56e03c140dfeb6.76012852</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC55ECAE-2DDD-4135-AEFF-5F3EE567C108</gtr:id><gtr:title>Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4494ad534c68bd921fe1766403b90372"><gtr:id>4494ad534c68bd921fe1766403b90372</gtr:id><gtr:otherNames>Gaymes TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>56e03c127da0f4.50538383</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D23F66B2-5171-471E-BCD8-B6AEE95DFFFA</gtr:id><gtr:title>Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4494ad534c68bd921fe1766403b90372"><gtr:id>4494ad534c68bd921fe1766403b90372</gtr:id><gtr:otherNames>Gaymes TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>56e03c0e3f42b6.39184314</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15C0C25D-948E-4B91-BCE8-865D06943764</gtr:id><gtr:title>Clinical grade lentiviral vector production for inherited skin disease</gtr:title><gtr:parentPublicationTitle>BRITISH JOURNAL OF DERMATOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd5343ece7f0d8feeda4751660d2972c"><gtr:id>bd5343ece7f0d8feeda4751660d2972c</gtr:id><gtr:otherNames>Semenova E.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>56e1ab8de38444.56101388</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB5EC494-A9F9-4279-BF69-D12F99975EBE</gtr:id><gtr:title>Immune Gene Therapy for Acute Myeloid Leukaemia</gtr:title><gtr:parentPublicationTitle>HUMAN GENE THERAPY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0a992e70ce8a24c7ebb268af00e9f601"><gtr:id>0a992e70ce8a24c7ebb268af00e9f601</gtr:id><gtr:otherNames>Farzaneh Farzin</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn><gtr:outcomeId>56e1ab8f946ed5.41535911</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F00B83F8-E648-4CB7-BDC8-61D2BB62344B</gtr:id><gtr:title>Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd2ca761a141ca7db238491b9127a7d8"><gtr:id>bd2ca761a141ca7db238491b9127a7d8</gtr:id><gtr:otherNames>Qasim W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>5900539beeb209.96652270</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB5E6921-D6FF-4553-B771-799916D37B12</gtr:id><gtr:title>Production of gene modified epithelial sheets for phase 1 clinical trial for Netherton Syndrome</gtr:title><gtr:parentPublicationTitle>HUMAN GENE THERAPY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/22c65c6ed8ee74bcaaec051db76bc0e5"><gtr:id>22c65c6ed8ee74bcaaec051db76bc0e5</gtr:id><gtr:otherNames>Ghani Sumera</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn><gtr:outcomeId>56e1ab8c7d6543.91560495</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F2814B5D-0787-4DD8-9996-C70754092F5A</gtr:id><gtr:title>Human CD80/IL2 lentivirus-transduced acute myeloid leukaemia (AML) cells promote natural killer (NK) cell activation and cytolytic activity: implications for a phase I clinical study.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6cfb5657d12e7354b8b9af96063c75a2"><gtr:id>6cfb5657d12e7354b8b9af96063c75a2</gtr:id><gtr:otherNames>Ingram W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>56e03c125e4906.07061907</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>29B957AC-D989-43BE-912B-C2314DE6C584</gtr:id><gtr:title>Cancer Immunotherapy: Whence and Whither.</gtr:title><gtr:parentPublicationTitle>Molecular cancer research : MCR</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a7fb87edde5ecfcbbea3c6235b124fe"><gtr:id>6a7fb87edde5ecfcbbea3c6235b124fe</gtr:id><gtr:otherNames>Stambrook PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1541-7786</gtr:issn><gtr:outcomeId>5900587814a842.79129537</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/E005896/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>